New knowledge will showcase considerably elevated and sustained minimal residual illness (MRD) negativity charges, reinforcing the potential of CARVYKTI to…
Our selection of the week's biggest research news and features sent directly to your inbox. Enter your email address, confirm you're happy to receive our emails.
Please contact salesdepartment
for further information at:
Sales@88.broker
Sign in to your account